Target
CCNG1
2 abstracts
Abstract
Effect of DeltaRex-G ± DeltaRex-G Plus (an FDA-approved drug) on advanced chemoresistant pancreatic cancer, sarcoma, and breast cancer.Org: William H. Isacoff, MD, Inc,
Abstract
Artificial intelligence analysis of CCNG1 expression in tumors: A novel biomarker in development for anti-CCNG1 targeted therapy.Org: Sarcoma Oncology Research Center, Santa Monica, CA, Santa Monica, CA, Dornsife College of Letters, University of Southern California, Los Angeles, CA, University of California Los Angeles,